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The aim of the study was to evaluate the safety profile of nilotinib administered to chronic myeloid leukemia (CML) at patients. The 
study was conducted from March 2018 to May 2019 and it included 20 patients with CML in chronic phase. Of these 20 patients, 17 had 
previously been treated with imatinib and 3 with hydroxyurea. The mean duration of treatment with Nilotinib was 6.75 months. In nine 
patients treated with nilotinib (400 mg), 55% complained of fatigue, 33% of headache and 22.2% of pruritus. In five patients treated with 
Nilotinib (600 mg), 20% complained of headache, 40% of fatigue and 20% of pruritus. In addition, in six patients treated with nilotinib 
(800 mg), 50% complained of headache and fatigue, 17% with pruritus and visual disorder was observed in 20% of cases. In the study, 
the adverse reactions were observed between the age of 20 and 40 and it was 7.1%, in contrast to the group of patients between the age of 
40 and 60 where the incidence of adverse reactions was 21.42%. The incidence of adverse reactions in patients in the age group over 60 
years it was 57.1%. In terms of gender, the incidence of adverse reactions was equal to 50% for both men and women. In conclusion, this 
study showed that treatment with nilotinib was well tolerated, with adverse reactions of an easy degree. Future evaluation is necessary in 
order to understanding the adverse reaction of nilotinib in comparison with other tyrosine kinase inhibitors. 
 






Chronic myeloid leukemia (CML) is cancer of bone 
marrow and white blood cells. The main feature of this 
leukemia is increased and unregulated growth of myeloid 
cells in the bone marrow and the accumulation of these 
cells in the blood. Abnormal cells observed in CML are:  
 
myeloid, erythroid, monocytic, megakaryocytic, B-
lymphoid, and occasionally T-lymphoid lineage (Faderl et 
al., 1999). The three stages in the development of CML 
are the blast phase, the phase of acceleration and the 
chronic phase. Most patients are randomly diagnosed as a 
result of an elevated white blood cell level during the 
chronic asymptomatic period. The most common findings 
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abdominal fullness, bleeding, purpura, splenomegaly, 
leucocytosis, thrombocytosis, and anemia (Faderl et al., 
1999). Recommendations for the management of CML 
have been elaborated by an international team of experts 
(Baccarani et al., 2006). Understanding the role of various 
agents and clinical hues between them in the treatment of 
CML is crucial to optimizing the clinical outcome of the 
patient. The era of introducing tyrosine kinase inhibitors 
(TKIs) in the treatment of CML completely changed the 
image and course of this life-threatening malignancy. 
Nilotinib belongs to the second generation of TKIs that 
has an extremely important role in the treatment of CML. 
It is one of the three drugs categorized in this category 
together with dasatinib and bosutinib (Etienne et al., 
2010).). Nilotinib can also be used after unsuccessful 
treatment with two different TKIs, and it becomes a third- 
generation drug by indication (Giles et al., 2007). We 
must agree that nilotinib has a leading role in the current 
management of CML, and has established its efficacy as a 
drug in the first and second line. The adverse reactions of 
this drug are common in clinical practice. Side effects of 
the higher level of the nilotinib that can endanger people's 
lives are often in relation to vital organs. The aim of this 
study was to elaborate and present the most common 
adverse reactions effects of nilotinib and to evaluate the 
safety profile of nilotinib administered to CML patients at 
the University Clinic for Hematology in Skopje, North 
Macedonia. It is important to note whether they are mild 
or life-threatening disorders. Adverse effects of imatinib 
and hydroxyurea as therapeutic options for CML are also 
conducted in this study. Monitoring the safety of nilotinib 
is of great importance to patients as well as clinicians. 
 
Materials and methods 
 
The study was conducted at the Clinic for 
Hematology in Skopje in the period from March 2018 to 
May 2019. The study included 20 patients from the whole 
state with CML in chronic phase. The average age of 
patients treated with nilotinib was 54.7 years. Furthermore, 
15% of this group smokes cigarettes, and 10% use alcohol 
occasionally. In our study, these 20 patients who are now 
on treatment with nilotinib, previously, 17 patients of them 
were on therapy with imatinib and 3 patients with 
hydroxyurea. The study considers the side effects of the 
treatment with all three drugs, with particular emphasis 
on the occurrence of the side effects with the treatment 
by nilotinib. The method of collecting data from the 
patients consisted of an analysis of medical records, with 
special attention being paid to the history of the disease 
of each patient individually, as well as in-depth 
interviews and retrospective data collection. Adverse 
effects events associated with the nilotinib treatment 
alone, as well as with previous imatinib and hydroxyurea 
treatment options were all recorded and analyzed. 
All patients with adverse events that occurred when 
the treatment was initiated were reported. In the case of 
discontinued treatment, they withdrew. 
 
Results and Discussion 
 
From 135 patients with CML, previously treated 
with imatinib and hydroxyurea, 20 patients were treated 
with nilotinib. At the same 20 patients, adverse reactions 
were observed while they were on the first line and then 
on the second line of treatment. Imatinib was approved for 
the treatment of bcr-abl positive patients with CML in 
2002. It is currently considered as an initial treatment in 
patients in a chronic phase. In those 15 patients with CML 
who had previously been treated with imatinib (400 mg), 
73.3% of these patients experienced periorbital edema and 
66.6% had muscular cramps. Apart from these, other 
adverse reactions such as legs pain (80%), erythema of the 
skin (20%) and disorder of hematological results (13.3%) 
has been reported. Meanwhile, in the other two patients 
who were on treatment with imatinib (800mg), in 50% 
there was an occurrence of pruritus, leg pain, periorbital 
edema, erythema of the skin, and disorder of 
hematological response for each adverse reaction 
individual (Fig. 1). 
In the three patients who had previously been treated 
with hydroxyurea, 66.6% reported pruritis and also 66.6% 
disorders of hematological results. 33.3% of them had leg 
pain, muscle pain and diarrhea for each adverse reaction 
individual (Fig. 2). 
These 20 patients listed above were redirected to 
nilotinib therapy. The mean duration of treatment with 
nilotinib in these 20 patients was 6.75 months. As for the 
frequency of adverse reactions, we have received the 
following results: from nine patients treated with nilotinib 
(400 mg) of 20, 55% complained of fatigue, 33% of 
headache and 22.2% of pruritus. In 44%, hyperlipidemia 
was registered and in 11.1% a disorder of the 
hematological response. Furthermore, five patients treated 
with nilotinib (600 mg), 20% complained of headache, 
40% of fatigue and 20% of pruritus. In 44%, 
hyperlipidemia was registered, in 40% a disorder of the 
hematological response and in 20% an allergic reaction 
was registered and due to those allergic reactions, the drug 
was discontinued. For curiosity, when using the dose of 
400 mg of this medication, the hearing disorder was 
observed in 20% of patients. In addition, in the 6 patients 
treated with nilotinib (800 mg), 50% complained of 
headache and fatigue and 17% of the pruritus. In 44% 
hyperlipidemia was registered, in 33% a disorder of 
hematological response and 67% an allergic reaction 
where the drug also was discontinued. Interesting, when 
using the dose of this medication (800 mg), the visual 
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On the other hand, in the 20 patients treated with 
nilotinib, adverse reactions were observed at almost all 
ages. At the patients under 20 years of age, no adverse 
reactions were observed. The appearance of adverse 
reactions between the age of 20 and 40 was 7.1%, in 
contrast to the group of patients between the age of 40 and 
60 where the incidence of adverse reactions was 21.42%. 
The incidence of adverse reactions in patients treated with 
nilotinib is highest in the age group over 60 years. It was 
57.1%. In terms of gender, the incidence of adverse 
reactions was equal to 50% for both men and women. 
Regarding the daily dose of nilotinib, adverse reactions 
were observed at 50% when using the daily dose of 800 
mg, 42.8% with a daily dose of 400 mg and 7.1% with a 
daily dose of 600 mg. Comorbidities have been reported 
in 28.57% of patients with adverse events. The most 
common comorbidities were from the neurological, 
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Fig. 3.    Distribution of most frequent adverse reactions in patients treated with nilotinib and its adverse reactions in 
correlation with administered dose. 
 
 
According to the WHO protocols, adverse reactions 
to the drug (ADR) have the following definition: "Any 
response to a drug that is harmful and unintentional, and 
which occurs at doses commonly used in humans for 
diagnosis, prophylaxis or therapy of the disease and for 
modifications of the physiological function". Negative 
reactions to drugs occur almost every day in any health 
institution. These can negatively affect the quality of life 
of the patient. It is a significant factor for morbidity and 
mortality (Gupta et al., 2011). Negative reactions can 
cause patients to lose their confidence, giving birth to 
negative emotions to the health profession and health 
institution. They can reach for self-treatment, which can 
result in negative reactions at a higher level (Schatz et al., 
2015). Within this, pharmacovigilance (PV) is defined as a 
sum of activities related to detection, evaluation, 
understanding and preventing adverse reactions or any 
other another drug problem. WHO has set up its own 
International drug monitoring program in response to the 
thalidomide disaster discovered in 1961. The goal of PV is 
to improve patient care and patient safety when using 
drugs. It also includes public support and creation of 
health programs by providing reliable, balanced 
information on effective risk-benefit assessment profile of 
drugs (Spina et al., 2016). 
CML is neoplasia of hematopoietic stem cell cells. 
The incidence of occurrence is 2 per 100 000 per year. 
The peak age is from 50 to 55 years old (Baccarani et al., 
2006). Philadelphia chromosome, a translocation product 
of chromosomes 9 and 22, is pathognomic for CML 
(Baccarani et al., 2009). Fusion protein acts as an active 
kinase. Kinase inhibitors such as imatinib block the 
activity of bcr-abl (Hochhaus et al., 2008). CML is one of 
the rare malignant diseases caused by one oncogene (bcr-
abl). This is the reason for the excellent efficacy of 
molecular therapy with CML (O'Brien et al., 2003). 
In general, imatinib is a very well tolerated drug. 
Serious adverse reactions mainly affect hemopoiesis and 
are partly caused by its effect against leukemia. A rare but 
potentially dangerous adverse reactions is congestive heart 
failure that is observed in 0.2% to 0.6% of cases on a 
worldwide level (Coutre et al., 2008). At the heart of our 
research was the pharmacovigilance of the drug nilotinib. 
It included activities related to the detection, assessment, 
understanding, and prevention of adverse effects of this 
drug. In 2007, nilotinib was approved for the treatment of 
bcr-abl positive patients with CML. Nilotinib is 
administered orally twice a day. The bioavailability of 
nilotinib is affected by food intake. Nilotinib inhibits 
BCR-ABL, PDGFR, and c-Kit kinases; it is a built-in base 
of competitive inhibition of binding sites of BCR-ABL 
adenosine triphosphate (ATP). Nilotinib can prevent 
tyrosine phosphorylation of intracellular proteins that help 
signal transduction. This, in turn, prevents cell 
proliferation and induces apoptosis of Ph + cells. Nilotinib 
is unique in that its power is increased by factor 30 
through imatinib due to its increased selectivity of ABL 
kinase and increased affinity for binding sites. Drugs that 
increase gastric pH may reduce the bioavailability of 
nilotinib. Because of this, the coadministration is not 
recommended (Carmen et al., 2008). For comparison, 
during a randomized study involving 717 patients in 
patients with newly diagnosed CML in the chronic phase 
of treatment with nilotinib, the lest common adverse 
reactions are: hematological toxicity in the form of 
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anemia, pleural and pericardial effusion with fluid 
maintenance, congestive heart failure, gastrointestinal 
bleeding and brain hemorrhage. The most commonly 
reported adverse reactions reported in this study are 
metabolic disorders (decreased appetite), headache, 
nausea, constipation, vomiting, abdominal pain, pain in 
the upper abdomen. Other commonly reported adverse 
reactions include rash, pruritus, myalgia, erythema, 
arthralgia and fatigue. Reporting of adverse reactions after 
approval of the drug is very important. It allows health 
professionals to monitor the balance between benefit and 
the risk of the drug (Etienne et al., 2010). 
The frequency of each adverse reaction in the study 
population should be correlated with the published data! 
Any specificity in the study population should be 




In summary, this study shows that treatment with 
nilotnib was well tolerated, with adverse reactions of an 
easy degree. None of the patients treated with nilotinib 
showed any life-threatening conditions such as pleural 
and pericardial effusion with fluid maintenance; 
congestive heart failure; gastrointestinal bleeding and 
hemorrhagic brain. In fact, nilotinib plays a very 
important role in the current management of CML. Proper 
evaluation of the side effects resulting from its use will 
open doctors' doors for better understanding of the site of 
nilotinib in comparison with other tyrosine kinase 
inhibitors in the treatment of CML. Clinical 
considerations of the toxicity of nilotinib and its 
interactions, models of resistance to drugs are of great 
importance to patients and their well-being. On the other 
hand, this approach will enable the optimization of 
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Целта на оваа студија беше да се процени безбедносниот профил на нилотинибот кој беше администриран кај 
пациенти со хронична миелоидна леукемија (ХМЛ). Оваа студија беше спроведена во период од март 2018 до мај 
2019 година и во неа беа опфатени 20 пациенти со ХМЛ во хронична фаза. Од овие 20 пациенти, 17 претходно беа 
третирани со имитаниб и 3 со хидроксиуреа. Просечното времетраење на третманот со Нилотниб беше 6,75 
месеци. Од девет пациенти кои беа третирани со нилотниб (400 мг), 55% се жалеа на замор, 33% на главоболка и 
22,2% на пруритус. Од вкупно пет пациенти третирани со нилотиниб (600 мг), 20% се пожалиле на главоболка, 
40% на замор и 20% на пруритус. Покрај тоа, од вкупно шест пациенти третирани со нилотиниб (800 мг), 50% се 
пожалиле на главоболка и замор, 17% на пруритус, додека пак нарушување на видот е забележано во 20% од 
случаите. Во оваа студија, несаканите реакции беа забележани на возраст меѓу 20 и 40 години, застапени со 
инциденца од 7,1%, наспроти групата на пациенти на возраст меѓу 40 и 60 години, каде што инциденцата на 
несакани реакции беше 21,42%. Инциденцата на несакани реакции кај пациенти од возрасна група над 60 години 
изнесуваше 57,1%. Во однос на полот, инциденцата на несакани реакции изнесуваше 50% и кај двата пола. 
Доаѓаме до заклучок дека оваа студија покажа дека третманот со нилотниб добро се толерира од страна на 
пациентите со појава на несакани реакции од лесен степен. Неопходни се истражувања и проценки во иднина со 
цел да се разбереат несаканите реакциии на нилотинибот во однос на останатите инхибитори на тирозин киназата. 
 
 
 
